ArticleEuropean journal of medical research2025
Association of triglyceride-glucose index and atherogenic index of plasma with sarcopenia across different glucose metabolism states: the mediating role of oxidative stress and chronic inflammation.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Association of baseline and cumulative CHG index with risk of new-onset sarcopenia in middle-aged and older adults.The journal of nutrition, health & aging · 2026Article
- Association between triglyceride-glucose index and sarcopenia in older adults without either dysglycemia or central obesity: a cross-sectional study from CHARLS.Open medicine (Warsaw, Poland) · 2026Article
- Association between the atherogenic index of plasma and prehypertension or hypertension among adults in Fujian, China: a population-based cross-sectional study.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe triglyceride-glucose (TyG) index and the atherogenic index of plasma (AIP) serve as biomarkers representing broad metabolic risks, and they are easy to obtain and cost-effective. However, there is a lack of extensive research investigating the relationship between these two metabolic markers and sarcopenia across various glucose metabolism statuses.
methodsData were obtained from the NHANES 2011-2016. A weighted logistic regression model was conducted to assess the relationships between AIP, TyG, and sarcopenia across all participants and subgroups categorized by glucose metabolism status. Restricted cubic spline analysis was applied to investigate their dose-response patterns. Additionally, mediation analysis was performed to explore the mediating influence of oxidative stress and chronic inflammation on the observed associations. Furthermore, the diagnostic accuracy of TyG and AIP in predicting sarcopenia was evaluated using receiver operating characteristic curve analysis.
resultsThis study included 3,680 participants, with 317 (8.6%) diagnosed with sarcopenia. After adjusting for all covariates, sarcopenia odds increased 84.9% (OR = 1.849, 95% CI: 1.305, 2.619, P = 0.0019) and 38.6% (OR = 1.386, 95% CI: 1.122, 1.712, P = 0.0057), respectively, with one-unit increment in AIP and TyG. We found positive linear dose-response relationships between both AIP (P
conclusionIn individuals with normal glucose metabolism, elevated AIP and TyG indices show a positive correlation with the occurrence of sarcopenia, and this relationship is partially mediated by the inflammation and oxidative stress present in the individual. Maintaining optimal glycemic and lipid metabolism is crucial for the primary prevention of sarcopenia and related diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.